Antonella Prisco

Dr. Antonella Prisco

Institute of Genetics and Biophysics – ABT, Naples, Italy
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 1999 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
PCPatrick S. Costello
Patrick S. Costello
AWAlice E. Walters
Alice E. Walters
PMP. Joseph Mee
P. Joseph Mee
MTMartin Turner
Martin Turner
LRLucinda F. Reynolds
Lucinda F. Reynolds
VTVictor L. J. Tybulewicz
Victor L. J. Tybulewicz
Vav is a GTP/GDP exchange factor (GEF) for members of the Rho-family of GTPases that is rapidly tyrosine-phosphorylated after engagement of the T cell receptor (TCR), suggesting that it may transduce signals from the receptor. T cells from mice made Vav-deficient by gene targeting (Vav−/−) fail to proliferate in response to TCR stimulation because they fail to secrete IL-2. We now show that this is due at least in part to the failure to initiateIL-2gene transcription. Furthermore, we analyze TCR-proximal signaling pathways inVav−/−T cells and show that despite normal activation of the Lck and ZAP-70 tyrosine kinases, the mutant cells have specific defects in TCR-induced intracellular calcium fluxes, in the activation of extracellular signal-regulated mitogen-activated protein kinases and in the activation of the NF-κB transcription factor. Finally, we show that the greatly reduced TCR-induced calcium flux of Vav-deficient T cells is an important cause of their proliferative defect, because restoration of the calcium flux with a calcium ionophore reverses the phenotype.

11 September 2012 in Computational and Mathematical Methods in Medicine
Verified
Journal Article
Open access
PDF file
FCFilippo Castiglione
Filippo Castiglione
Francesca MantileFrancesca Mantile
Francesca Mantile
PBP. De Berardinis
P. De Berardinis
Antonella PriscoAntonella Prisco
Antonella Prisco
The immune system is able to respond more vigorously to the second contact with a given antigen than to the first contact. Vaccination protocols generally include at least two doses, in order to obtain high antibody titers. We want to analyze the relation between the time elapsed from the first dose (priming) and the second dose (boost) on the antibody titers. In this paper, we couplein vivoexperiments with computer simulations to assess the effect of delaying the second injection. We observe that an interval of several weeks between the prime and the boost is necessary to obtain optimal antibody responses.

22 February 2010 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
MRMaria Cristina Rosi
Maria Cristina Rosi
ILIlaria Luccarini
Ilaria Luccarini
CGCristina Grossi
Cristina Grossi
AFAnna Fiorentini
Anna Fiorentini
MSMaria Grazia Spillantini
Maria Grazia Spillantini
FCFiorella Casamenti
Fiorella Casamenti
J. Neurochem. (2010) 112, 1539–1551. To investigate the role of the Wnt inhibitor Dickkopf‐1 (DKK‐1) in the pathophysiology of neurodegenerative diseases, we analysed DKK‐1 expression and localization in transgenic mouse models expressing familial Alzheimer’s disease mutations and a frontotemporal dementia mutation. A significant increase of DKK‐1 expression was found in the diseased brain areas of all transgenic lines, where it co‐localized with hyperphosphorylated tau‐bearing neurons. In TgCRND8 mice, DKK‐1 immunoreactivity was detected in neurons surrounding amyloid deposits and within the choline acetyltransferase‐positive neurons of the basal forebrain. Active glycogen synthase kinase‐3 (GSK‐3) was found to co‐localize with DKK‐1 and phospho‐tau staining. Downstream to GSK‐3, a significant reduction in β‐catenin translocation to the nucleus, indicative of impaired Wnt signaling functions, was found as well. Cumulatively, our findings indicate that DKK‐1 expression is associated with events that lead to neuronal death in neurodegenerative diseases and support a role for DKK‐1 as a key mediator of neurodegeneration with therapeutic potential.

1 March 2009 in Biophysical Journal
Verified
Journal Article
Closed access
MNMario Nicodemi
Mario Nicodemi
Antonella PriscoAntonella Prisco
Antonella Prisco

2 April 2003 in Immunological Reviews
Verified
Journal Article
Closed access
PDF file
VTVictor L. J. Tybulewicz
Victor L. J. Tybulewicz
LALaurence Ardouin
Laurence Ardouin
Antonella PriscoAntonella Prisco
Antonella Prisco
LRLucinda F. Reynolds
Lucinda F. Reynolds

24 October 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
PSPaola Stolfi
Paola Stolfi
FCFilippo Castiglione
Filippo Castiglione
EMEnrico Mastrostefano
Enrico Mastrostefano
IBImmacolata Di Biase
Immacolata Di Biase
SBSebastiano Di Biase
Sebastiano Di Biase
Antonella PriscoAntonella Prisco
Antonella Prisco
Background: The immune response to adenoviral COVID-19 vaccines is affected by the interval between doses. The optimal interval is unknown.Aim: We aim to explore in-silico the effect of the interval between vaccine administrations on immunogenicity and to analyze the contribution of pre-existing levels of antibodies, plasma cells, and memory B and T lymphocytes.Methods: We used a stochastic agent-based immune simulation platform to simulate two-dose and three-dose vaccination protocols with an adenoviral vaccine. We identified the model’s parameters fitting anti-Spike antibody levels from individuals immunized with the COVID-19 vaccine AstraZeneca (ChAdOx1-S, Vaxzevria). We used several statistical methods, such as principal component analysis and binary classification, to analyze the correlation between pre-existing levels of antibodies, plasma cells, and memory B and T cells to the magnitude of the antibody response following a booster dose.Results and conclusions: We find that the magnitude of the antibody response to a booster depends on the number of pre-existing memory B cells, which, in turn, is highly correlated to the number of T helper cells and plasma cells, and the antibody titers. Pre-existing memory T cytotoxic cells and antibodies directly influence antigen availability hence limiting the magnitude of the immune response. The optimal immunogenicity of the third dose is achieved over a large time window, spanning from 6 to 16 months after the second dose. Interestingly, after any vaccine dose, individuals can be classified into two groups, sustainers and decayers, that differ in the kinetics of decline of their antibody titers due to differences in long-lived plasma cells. This suggests that the decayers may benefit from a tailored boosting schedule with a shorter interval to avoid the temporary loss of serological immunity.